

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV

Anne Rechtien, Laura Richert, Hadrien Lorenzo, Gloria Martrus, Boris P. Hejblum, Christine Dahlke, Rahel Kasonta, Madeleine Zinser, Hans Stubbe, Urte Matschl, et al.

► **To cite this version:**

Anne Rechtien, Laura Richert, Hadrien Lorenzo, Gloria Martrus, Boris P. Hejblum, et al.. Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Reports, Elsevier Inc, 2017, 20 (9), pp.2251 - 2261. 10.1016/j.celrep.2017.08.023 . hal-01579246

HAL Id: hal-01579246

<https://hal.inria.fr/hal-01579246>

Submitted on 6 Oct 2018


HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Cell Reports

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV

Graphical Abstract



Authors

Anne Rechten, Laura Richert, Hadrien Lorenzo, ..., Rodolphe Thiébaud, Marcus Altfeld, Marylyn Addo

Correspondence

anne.rechten@leibniz-hpi.de (A.R.),
 m.addo@uke.de (M.A.)

In Brief

Rechten et al. apply a systems vaccinology approach to examine the early innate immune responses elicited by the Ebola vaccine rVSV-ZEBOV. They find that early innate immune responses, with IP-10 as an independent soluble marker, correlate with EBOV-GP-specific antibody induction.

Highlights

- 5 early innate markers correlate with antibody response to Ebola vaccine rVSV-ZEBOV
- IP-10 on day 3 after vaccination is an independent correlate of antibody induction
- RNA-seq analysis identifies early gene expression signature linked to IP-10

Accession Numbers

GSE97590



Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV

Anne Rechten,^{1,2,3,8,9,*} Laura Richert,^{3,4,5,8} Hadrien Lorenzo,^{4,5} Gloria Martrus,³ Boris Hejblum,^{4,5} Christine Dahlke,^{1,2} Rahel Kasonta,^{1,2} Madeleine Zinser,¹ Hans Stubbe,^{2,6} Urte Matschl,³ Ansgar Lohse,¹ Verena Krähling,⁷ Markus Eickmann,⁷ Stephan Becker,⁷ VEBCON Consortium, Rodolphe Thiébaud,^{4,5} Marcus Altfeld,^{3,8} and Marylyn Addo^{1,2,8,*}

¹University Medical Center Hamburg-Eppendorf, 1st Department of Medicine, 20246 Hamburg, Germany

²German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 20246 Hamburg, Germany

³Heinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany

⁴INSERM U1219, INRIA SISTM, Bordeaux University, Bordeaux, France

⁵Vaccine Research Institute, Creteil, France

⁶Division of Infectious Diseases, Department of Medicine IV, LMU, 80336 Munich, Germany

⁷Philipps University Marburg, Institute for Virology, 35043 Marburg, Germany

⁸These authors contributed equally

⁹Lead Contact

*Correspondence: anne.rechten@leibniz-hpi.de (A.R.), m.addo@uke.de (M.A.)

<http://dx.doi.org/10.1016/j.celrep.2017.08.023>

SUMMARY

Predicting vaccine efficacy remains a challenge. We used a systems vaccinology approach to identify early innate immune correlates of antibody induction in humans receiving the Ebola vaccine rVSV-ZEBOV. Blood samples from days 0, 1, 3, 7, and 14 were analyzed for changes in cytokine levels, innate immune cell subsets, and gene expression. Integrative statistical analyses with cross-validation identified a signature of 5 early innate markers correlating with antibody titers on day 28 and beyond. Among those, IP-10 on day 3 and MFI of CXCR6 on NK cells on day 1 were independent correlates. Consistently, we found an early gene expression signature linked to IP-10. This comprehensive characterization of early innate immune responses to the rVSV-ZEBOV vaccine in humans revealed immune signatures linked to IP-10. These results suggest correlates of vaccine-induced antibody induction and provide a rationale to explore strategies for augmenting the effectiveness of vaccines through manipulation of IP-10.

INTRODUCTION

Recent outbreaks of emerging infections, caused by viruses such as Ebola, Middle East Respiratory Syndrome (MERS), Coronavirus, and Zika Virus, represent a global threat and emphasize the critical need for new vaccine concepts and vectors and for rapid clinical development. However, predicting and achieving vaccine efficacy remains a major challenge in the acceleration of vaccine development. Systems vaccinology approaches can assist with the identification of early immune signatures predictive of vaccine immunogenicity (Pulendran et al.,

2010). Previous studies have investigated the potential of early innate immune signatures to predict the antibody response to vaccines, such as the yellow fever or influenza vaccines (Nakaya et al., 2011; Querec et al., 2009; Gaucher et al., 2008; Furman et al., 2013), among others (Li et al., 2014), but it remains unknown whether molecular signatures can be identified that can be used to predict immune responses to novel vaccines. Here we applied a systems vaccinology approach to disentangle the early innate immune responses elicited by the Ebola vaccine rVSV-Zaire Ebola virus (ZEBOV) to identify innate immune responses correlating with Ebola virus (EBOV)-glycoprotein (GP)-specific antibody induction. This replication-competent recombinant vaccine candidate is based on the vesicular stomatitis virus (rVSV)-based vaccine vector, for which limited data on immune responses and no innate immunity profiles in humans have been reported thus far. rVSV-ZEBOV represents one of the most promising Ebola vaccine candidates to date, with anticipated licensure expected soon. This vaccine has shown to be protective in relevant EBOV animal challenge models, including non-human primates (NHPs), where it conferred 100% protection (Jones et al., 2005; Qiu et al., 2009; Geisbert et al., 2008,2009). Furthermore, it is the only EBOV candidate vaccine for which an efficacy evaluation against the risk of infection in humans was possible. A cluster-randomized ring vaccination trial conducted in Guinea in 2015 showed promising results, demonstrating that a strategy of contact tracing and immediate ring vaccination of contacts with the rVSV-ZEBOV vaccine protects against Ebola virus disease compared with controls (Henao-Restrepo et al., 2017). While this ring vaccination trial was focused on clinical endpoints only and did not assess immune responses induced by the vaccine, the safety and immunogenicity of vaccination with rVSV-ZEBOV were evaluated in 2014–2015 in a number of investigator-initiated dose-escalation phase 1 clinical trials coordinated through a World Health Organization (WHO)-led African and European VSV-Ebola Consortium (VEBCON), which informed dose selection for the



efficacy trials. These harmonized but independent investigator-initiated phase I trials were completed in 2015 and took place at four different international sites, including the University Medical Center Hamburg-Eppendorf (UKE) in Germany (Agnandji et al., 2016). In these trials, vaccination with rVSV-ZEBOV was shown to be immunogenic and induced GP-specific antibodies in all participants (Agnandji et al., 2016). However, the immunological mechanisms leading to antibody induction, in particular the role of early innate immune responses to this vaccine vector, remain to be elucidated.

The systems vaccinology approach presented here comprehensively dissects innate immunity profiles to rVSV-ZEBOV and reveals strong and early innate immune activation following vaccination. A subset of early innate markers, encompassing interferon- γ -inducible protein 10 (IP-10) and subsets of monocytes, dendritic cells, and natural killer (NK) cells as well as an early gene signature linked to the IP-10 pathway, were identified as innate immune signatures that correlate with the GP-specific antibody response on day 28 and beyond. Because human data on the recombinant VSV vaccine platform are scarce, our study makes important contributions to the understanding of the immunological properties of this vaccine in humans and may provide unique insights for future use of this vector technology in emergency vaccines, including candidate vaccines currently in development against Zika virus (Betancourt et al., 2017).

RESULTS

Induction of Antiviral Plasma Cytokines Starts on Day 1 after Vaccination

Human data on immunity induced by vaccines based on rVSV vectors are scarce. We therefore first studied early plasma cytokine responses induced by the vaccine. Plasma was isolated on days 0, 1, 3, 7, and 14 after vaccination and analyzed for concentration levels of interleukin-2 (IL-2), IL-6, IL-12 p70, IL-10, interleukin-1 receptor antagonist (IL-1RA), interferon- γ (IFN- γ), IFN- α , tumor necrosis factor alpha (TNF- α), TNF- β , macrophage-inflammatory protein-1 α (MIP-1 α), MIP-1 β , monocyte chemoattractant protein-1 (MCP-1) and IP-10 using a Luminex assay. The respective cytokines were selected based on their reported roles in orchestrating host immune responses to vaccines (Querec et al., 2009; Nakaya et al., 2011; Barouch et al., 2013; Teigler et al., 2012). The vaccine rVSV-ZEBOV induced a rapid and robust increase in cytokine levels, with a maximum peak as early as day 1. Significant increases in concentration levels were noted for IP-10 (CXCL-10) on days 1 and 3 and for MCP-1 and MIP-1 β on day 1 relative to their expression on day 0 (Wilcoxon signed-rank test, false discovery rate [FDR]-adjusted $p < 0.001$ for each cytokine; Figures 1A and 1B). Cytokine levels of MCP-1 and IP-10 were vaccine dose-dependent, with the highest levels observed in higher vaccine dose group 2 receiving 20×10^6 plaque-forming units (PFUs) compared with the lower dose group receiving 3×10^6 PFUs (Wilcoxon rank-sum test for between-group comparison on day 1; FDR-adjusted $p = 0.003$ and 0.048, respectively; Figure 1C). The remaining 10 cytokines had concentration levels below the range of the standard curve in >50% of the measurements at several time points, and no statistical analyses were performed on these cytokines. Altogether, we

show here that rVSV-ZEBOV leads to a significant and early induction of the cytokines IP-10, MCP-1, and MIP-1 β , with maximum plasma peak levels on day 1 after vaccination.

The rVSV-ZEBOV Vaccine Induces Expansion of Activated Innate Cell Subsets and Increased Expression of Innate Immune Markers

To gain additional insights into the underlying innate immune responses to the rVSV-ZEBOV vaccine, we further analyzed peripheral blood mononuclear cells (PBMCs) for changes in frequency and activation status of innate immune cell subsets, including myeloid and plasmacytoid dendritic cells (mDCs and pDCs, respectively), monocytes, and NK cells. Vaccination with rVSV-ZEBOV led to a strong and early induction of a wide spectrum of activating molecules and upregulation of costimulatory molecules on both antigen-presenting cells (monocytes and DCs) and NK cells (Figure 2). Significant modulations were seen in the frequency of CD86+/CD40+ mDCs and pDCs as well as CD16+ inflammatory monocytes, accompanied by an increase in the mean fluorescence intensity (MFI) of CD40 on pDCs and CD86 on mDCs. Analysis also revealed significant upregulation of several activation markers on NK cells, including NKG2D and CD38 (Figure 2). The entire spectrum of assessed innate surface markers is shown in Table S1. The kinetics of surface marker expression and frequency differed among the distinct cell subsets, with peak values either reached by day 1 or day 3 following vaccination (Table S1). For all markers, frequency and surface expression declined again following day 3 after vaccination (Figure 2; Table S1).

Overall, rVSV-ZEBOV vaccination resulted in significant and early activation of NK cells, (inflammatory) monocytes, and DCs between day 1 and day 3 after vaccination.

EBOV-GP-Binding Antibody Responses Induced by the Vaccine

GP-specific antibody responses were measured using an ELISA in two centralized laboratories (Marburg, Germany and United States Army Medical Research Institute for Infectious Diseases [USAMRIID], USA) on days 0, 7, 14, 28, 56, 84, and 180. EBOV-GP-binding antibodies were measured using an ELISA against the homologous GP of the Zaire-Kikwit strain (short Kikwit-GP-specific antibodies) by USAMRIID on day 0 and day 28 (these were the only time points available at the time of analysis) or against inactivated whole virions of the Zaire-Gueckedou strain (short Gueckedou-GP-specific antibodies) in Marburg at all available time points (days 28, 56, 84, and 180) (Agnandji et al., 2016). On day 28 after vaccination, the rVSV-ZEBOV vaccine induced glycoprotein-specific antibodies in all participants at all doses, demonstrating its robust immunogenicity (Figure S1). The levels of EBOV-GP-binding antibodies were durable over time until day 180 (Figure 3), as published previously (Agnandji et al., 2016).

Identification of Vaccine-Induced Early Innate Immune Responses that Correlate with Later EBOV-GP Antibody Responses Using a Multidimensional Statistical Approach

We next studied whether any of the cytokines and/or cell surface markers measured on days 0, 1, and 3 after vaccination or a




Figure 1. A Strong Increase in Cytokine Levels as Early as Day 1 after Vaccination

(A) Graphs showing box and whisker plots with the minimum, first quartile, median, third quartile, and maximum of the cytokine levels on the different days. Two-sided Wilcoxon signed-rank test was performed for within-group comparisons of post-vaccination time points to baseline (d0) across both dose groups (n = 20 trial participants). Significant p values adjusted for multiple testing by adaptive FDR are shown for the day 1 to day 0 and day 3 to day 0 comparisons.

(B) Heatmap reflecting the plasma concentration of 13 cytokines on days 0, 1, 3, 7, and 14 for both vaccine dose groups (group 1 [n = 10 trial participants] with 3 × 10⁶ PFUs in orange symbols, group 2 [n = 10 trial participants] with 20 × 10⁶ PFUs in blue symbols on the top part of the figure). For generation of the heatmap, plasma concentration levels below the range of the standard curve were replaced with a value of 0 pg/mL, and all values per cytokine were then standardized.

(C) Box and whisker plots with the minimum, first quartile, median, third quartile, and maximum of the cytokine levels of MCP-1 and IP-10 for each dose group on day 1 (n = 10 participants per dose group). Two-sided Wilcoxon rank-sum test was performed for between-group comparisons. The p values are adjusted for multiple testing by adaptive FDR. Data were generated from one experiment. Samples were measured in duplicates.




Figure 2. Early Vaccine-Induced Changes in Frequency and Activation Status of Innate Immune Cell Subsets

(A and B) Graphs show box and whisker plots with the minimum, first quartile, median, third quartile, and maximum. Shown are the changes in frequency of selected innate cell subsets (A) and a summary of the modulated MFI on selected subsets of DCs, (inflammatory CD16+) monocytes, and NK cells between day 0 and day 14 (B). Two-sided Wilcoxon signed rank-test was performed for within-group comparisons of post-vaccination time points to baseline (d0) across both dose groups (n = 20 trial participants). Significant p values, adjusted for multiple testing by adaptive FDR, are shown for the day 1 to day 0 and day 3 to day 0 comparisons. Data were generated from one experiment. See also Table S1.

combination thereof represented an early innate immune signature associated with later antibody responses. A multidimensional statistical analysis method was used to assess the early innate immune responses between day 0 and day 3 as correlates of the subsequent EBOV-GP-specific antibody responses. Given the high number of predictor variables (435 early innate immune marker variables across day 0, day 1, and day 3) and the small sample size (20 trial participants), we took advantage of the full spectrum of antibody response measurements between day 28 and day 180 to increase the amount of response information in the model using sparse partial least-squares (sPLS). Cross-validated down-selection resulted in a single sPLS component including five early innate markers as correlates of the later antibody responses (with 49%–67% of the variance of each of the five antibody response measurements explained; Table S2). The correlation matrix between the selected innate markers and the antibody response variables is shown in Figure 4 (additional numerical results are shown in Table S3 and correlations among innate markers in Figure S2).

IP-10 plasma levels on day 3, the frequency of CD56^{bright} NK cells on day 3, and the mean fluorescence intensity of CXCR6 on CD56^{dim} NK cells on day 1 post-vaccination were positively correlated with antibody responses on day 28 and onward. Antibody levels on day 28 were most strongly correlated with IP-10.

The other two innate immune response markers, related to CD86 expression on monocytes on day 3, were negatively correlated with antibody responses. Absolute numbers of these markers identified through flow cytometry are shown in Table S4. Taken together, our data reveal a signature of five early innate immune markers that correlate with the GP-specific vaccine-induced antibody response on day 28 and beyond.

Independent Innate Predictors of Antibody Response on Day 28

To further disentangle whether the effects of the five selected innate markers were independent from each other, we used multivariable linear regressions with a stepwise bottom-up variable selection, starting with the five innate markers identified by the sPLS analysis above. We assessed the independent determinants of the Gueckedou-GP-specific antibody response on day 28, an immunogenicity time point of primary interest in ongoing vaccine trials.

Two significant independent determinants were retained in the final multivariable model by this method (Table 1). The plasma level of IP-10 on day 3 was a significant positive determinant of the day 28 antibody response: per 1,000 pg/mL increase in IP-10 plasma levels on day 3, the level of Gueckedou-specific antibodies increased by 0.33 log optical density units. The second




Figure 3. Individual Changes in Gueckedou-GP-Specific Antibody Levels Over Time

Each line corresponds to an individual trial participant. Participants in the 3×10^6 PFU group are shown in blue, and participants in the 20×10^6 PFU group are shown in orange. Negative optical density (OD) values were imputed as the lowest positive observed OD value (0.003). See also [Figure S1](#).

significant positive determinant was the mean fluorescence intensity of CXCR6 on CD56^{dim} NK cells on day 1: per 1,000 units of increase in MFI, the level of Gueckedou-specific antibodies increased by 1.37 log optical density units. Although the predictive value of the model was imperfect (root square residuals [RSRs] leave-one-out: 0.77, SD 0.64), it explained 55% of the variability of the antibody response measured on day 28.

When the Kikwit GP-specific antibody levels on day 28 were used as a response variable instead of Gueckedou-GP-specific antibodies, plasma IP-10 on day 3 was the only significant determinant in the final model (0.48 increase in Kikwit GP-specific antibody log ELISA units/mL per 1,000 pg/mL increase in plasma IP-10; 95% confidence interval, 0.28; 0.67, $p < 0.001$; adjusted R^2 , 0.56; RSR leave-one-out, 0.69 [SD, 0.50]).

Altogether, the final multivariable linear model identified two early innate markers positively and independently associated with later EBOV-Gueckedou-GP-specific antibody responses. In particular, among the five markers in the early innate signature identified by the sPLS model, plasma IP-10 on day 3 was found to be a statistically significant, positive determinant of antibody responses on day 28, thus being independently associated with the day 28 antibody response level regardless of the levels of the four other early markers.

Next-Generation RNA Sequencing of Full Blood Shows Differential Gene Expression after Vaccination

We next sought to assess whether early vaccine effects were also identifiable in gene expression levels from whole blood sampled on days 0, 1, 3, and 7. Differential gene expression from the day 0 baseline was investigated gene-wise using the voom/limma method ([Law et al., 2014](#)). Sequences from 60,417 genes were measured, of which 19,797 were identified as protein-coding. After excluding genes with very low expression levels (mean count < 5), 18,301 genes were included in the statistical analyses.

The highest number of differentially expressed genes was observed on day 1 after vaccination, with 10,123 genes being significantly differentially expressed compared with day 0 ([Figure 5A](#)), with a larger up- than downregulation ([Figure 5B](#)). When analyzing differential expression on day 1 in each dose group separately, a dose effect was apparent, with 3,509 differentially expressed genes in the lower dose group and 19,539 in the higher dose group ([Figure S3](#)). Among the 10,123 differentially expressed genes on day 1 overall (both dose groups combined), the 10 genes with the largest fold changes included CXCL10, the gene encoding for IP-10 ([Table 2](#)).

In canonical pathway analyses including all significant genes on day 1 (Ingenuity Pathways Analysis software), the top enriched pathways included the interferon signaling pathway, the pathway of pattern recognition receptors in recognition of bacteria and viruses, and the inflammasome pathway, which were all upregulated ([Figure S4](#)).

Early Gene Expression Signature Linked to the IP-10 Pathway Correlates with Later GP-Specific Antibody Responses to the Vaccine

We next assessed whether early gene expression correlates of later antibody responses could be identified. To do so, we used an unbiased approach, including gene expression levels of all analyzed genes (18,301 genes) on days 1, 3, and 7 as potential predictors regardless of their differential expression level. We again used sPLS to down-select an early signature of genes correlating with the multivariate antibody response measurements between day 28 and day 180. Bootstrapping methods were used in addition to leave-one-out cross-validation to avoid overfitting of the model.

Leave-one-out cross-validation identified a signature of gene expression comprising 15 genes on a single component that correlated with the later antibody responses ([Figure S5](#)). Of these, two genes were consistently more often selected using bootstrapping methods than the other genes. The first gene was TIFA (TRAF-interacting protein with forkhead-associated domain) on day 1, which is related to the IP-10 pathway ([Figure 6A](#)). The second gene was SLC6A9 (solute carrier family 6 member 9) on day 3, which is not known to be related to the IP-10 pathway. Between these two genes, only TIFA was significantly differentially expressed at the concerned time point compared with baseline (D0 log₂ mean expression, 3.38; D1 log₂ fold change, 1.33; multiplicity-adjusted p value, 1.14×10^{-9} ; [Figure S6](#)).

Because pathway analyses were based on external curated databases (Ingenuity Pathways Analysis), we next assessed whether the correlations reflecting the identified pathways were also present in our dataset. [Figure 6B](#) shows the correlations between TIFA gene expression on day 1, representative intermediate genes of each pathway on day 1, CXCL10 gene expression on day 1 or 3, and plasma IP-10 cytokine concentration on day 1 or 3. These analyses identified the expected correlations between TIFA and the CXCL10 pathway in our dataset and suggested that the main pathway activation was via the nuclear factor κ B (NF- κ B) complex (strongest positive correlations between TIFA and NFKB1 and NFKB2, respectively, which are the genes representative of this complex). In the differential




Figure 4. Correlation Matrix (Pearson Correlation Coefficients) between Each of the Five Early Cell Populations, Cytokine Immune Response Markers Selected by sPLS, and the Antibody Responses between day 28 and day 180 (n = 20 Trial Participants)

The matrix shows positive correlations with the corresponding antibody responses in blue and negative correlations in red. The stronger the intensity of the color, the stronger is the correlation. See also [Figure S1](#), [Tables S2](#) and [S3](#), and [Table S4](#).

gene expression analyses, the NFKB1, NFKB2, and CXCL10 genes were also among the differentially upregulated genes at the indicated time points compared with baseline.

DISCUSSION

The recent and unprecedented outbreak of Ebola virus disease (EVD) in West Africa led to the evaluation of the VSV-based Ebola vaccine rVSV-ZEBOV in an open-label, dose escalation, single-center phase 1 trial at the UKE. The vaccine induced EBOV-GP-specific antibodies in all trial participants, documenting its immunogenicity ([Agnandji et al., 2016](#)). Despite the uncertainty about which immune responses actually serve as correlates of protection from Ebola virus disease, initial studies suggested that GP-specific antibodies play a crucial role in conferring protection following vaccination in NHPs and vaccinated guinea pigs ([Jones et al., 2005](#); [Bukreyev et al., 2007](#); [Wong et al., 2012](#); [Warfield et al., 2007](#)). Using a systems vaccinology approach to identify unique early innate immune signatures of emergency vaccines fills critical knowledge gaps and will facilitate the strategic design of future immunotherapeutic interventions.

In this study, we applied high-throughput technologies coupled with methods for integrative data analyses as powerful tools to investigate a large spectrum of innate cell surface markers, cytokines, and gene expression to determine whether early innate immune responses can serve as correlates of antibody induction in response to the rVSV-ZEBOV vaccine.

Longitudinal assessment of early innate immune responses showed a strong and early activation of innate immune responses as early as day 1 after vaccination. IP-10, MIP-1 β , and MCP-1 were significantly induced by day 1 after vaccination, with dose-dependent peak levels of MCP-1 and IP-10. Increase

in IP-10 levels after vaccination has also been reported in previous studies investigating immune responses to the yellow fever vaccine ([Querec et al., 2009](#)) and the inactivated trivalent inactivated influenza vaccine (TIV) ([Nakaya et al., 2011](#)). However, these studies did not include an analysis of any immune changes as early as day 1 and reported peak levels of cytokine levels on day 3 following vaccination. It therefore remains unclear whether the true peak was missed or is

indeed reached at a later time point in these studies because dynamics of cytokine expression may depend on the vaccine or vector being used. In line with previous results of the aforementioned vaccine studies, we also observed a strong increase in the frequency of CD16+ inflammatory monocytes and CD86+ DCs and monocytes. We found peak expression to be reached as early as day 3 in our studies compared with day 7, as reported for the yellow fever vaccine ([Querec et al., 2009](#)), indicating that dynamics in surface marker expression on innate immune cells may indeed depend on the specific vaccine being tested. Changes in frequency or expression of further activating markers on antigen-presenting cells, as revealed by our study, have not been reported before. Particularly, changes in frequency and phenotype of NK cells following vaccination with rVSV-ZEBOV in humans have not been described in any previous vaccine study. Our data thus provide insights into the full picture of early vaccine-induced key mediators involved in the innate immune response to vaccination. NK cells have previously been suggested as critical players in the mediation of early protection against Ebola infection in NHPs; [Marzi et al. \(2015\)](#) showed that vaccination with rVSV-ZEBOV protected macaques against a lethal challenge with the West African EBOV-Makona strain. Intriguingly, complete and partial protection was achieved with a single dose given as late as 7 or 3 days before challenge, respectively, even before an adaptive antibody response had been developed ([Marzi et al., 2015](#)). Thus, [Marzi et al. \(2015\)](#) implicated a role for NK cells in conferring this early-induced protection after vaccination because the cytokine signature induced by the vaccine was highly suggestive of NK cell activation, eventually resulting in NK cell-mediated killing of virus-infected cells. Their findings suggest that vaccination-induced activation of NK cells could contribute to control of EBOV replication before

Table 1. Multivariable Linear Modeling Results

Determinant	Regression Coefficient Estimate	95% Confidence Interval	p Value
Intercept	-5.61	[-8.03; -3:19]	< 10 ⁻³
Plasma IP-10 level on day 3 (per 1000 pg/mL change)	0.33	[0.05; 0.60]	0.02
MFI of CXCR6 on CD56 ^{dim} NK cells on day 1 (per 1,000 MFI change)	1.37	[0.15; 2.58]	0.03

Model selection criteria: adjusted R², 0.55; RSR leave-one-out, 0.77 (SD, 0.64).

specific antibody responses have developed. Furthermore, NK cells have also been implicated in survival of EBOV infections, showing a decisive role for NK cells during lethal Ebola virus infection (Feldmann et al., 2007; Warfield et al., 2004). In the present study, MFI of CXCR6 on CD56^{dim} NK cells and frequency of CD56^{bright} NK cells were identified as positive correlates of the GP-specific antibody response, supporting the role of NK cells in shaping subsequent adaptive immunity. CXCR6, a member of the seven-transmembrane domain G protein-coupled chemokine receptor (CKR) family was shown to act as a chemokine-traffic molecule and is indispensable for persistence of NK cell memory of haptens and viruses in animal models (Shimaoka et al., 2000; Paust and von Andrian, 2011; Paust et al., 2010). Future studies should explore whether these markers display a functional role in vaccine-induced generation of antibody responses.

Although IP-10 on day 3, CXCR6 on day 1, and the frequency of CD56^{bright} NK cells on day 3 showed a positive correlation with antibody responses, antigen-presenting cells (inflammatory monocytes and mDCs) expressing the activating marker CD86 showed a negative association. CD86 is a costimulatory molecule that provides key signals required for T cell activation (Fanslow et al., 1994; Lu et al., 1996; Sansom et al., 2003). A negative effect of vaccine-induced inflammatory monocytes on T cell proliferation and antibody production has been reported previously in mice (Mitchell et al., 2012). Here, vaccination-induced inflammation, although necessary for effective immunity, also generated strong counter-regulatory immune responses that were mediated primarily by inflammatory monocytes through suppression of T cell responses. It was demonstrated that suppression of T cell help eventually led to reduced antibody titers in vaccinated mice, implicating a potential role for inhibition of monocyte-mediated inhibitory responses as an effective strategy for enhancing vaccine immunity. Because DCs share many features with monocytes as antigen-presenting cells, a counter-regulatory effect on the adaptive immune responses elicited by these cells may also be arguable but has yet to be demonstrated. Taken together, these data suggest that activated (inflammatory) monocytes have a negative effect on the generation of GP-specific antibody responses, reflecting a counter-regulatory, suppressive effect of these antigen-presenting cells on the development of adaptive immune responses.




Figure 5. Differentially Expressed Genes after Vaccination (n = 18 Trial Participants with Available RNA-Seq Data)

(A) Venn diagram of the number of differentially expressed genes per post-vaccination time point.

(B) Distribution of log fold changes on day 1. Each dot corresponds to a gene, plotted according to its mean log expression on the x axis and its log fold change on the y axis. Red dots indicate statistically significant differentially expressed genes.

See also Figures S2 and S3.

The only soluble positive correlate of the GP-specific antibody response on day 28, IP-10, was statistically independent from the other down-selected innate immune markers. IP-10 is one of the most potent cytokines secreted from monocytes and DCs (Dufour et al., 2002). It is secreted from cells stimulated with type I and II IFNs and is a strong chemoattractant for activated T cells. IP-10 can generate and amplify antitumor immunity through recruitment of antigen-specific T cells to antigen-presenting DCs in draining lymph nodes (Christensen et al., 2006). Interestingly, studies have shown that, when linked to a model tumor antigen, IP-10 can increase tumor antigen-specific T cell immune responses in mice because of both enhanced antigen

Table 2. List of 10 Differentially Expressed Genes on Day 1 with the Largest Fold Changes

Ensemble Gene ID	Gene Name	Day 0 Log2 Mean Expression	Day 1 log2 Fold Change	p Value
ENSG00000108700	CCL8	-1.79	9.15	1.33E-18
ENSG00000108691	CCL2	0.20	8.55	1.69E-18
ENSG00000078081	LAMP3	3.15	8.02	2.22E-27
ENSG00000169245	CXCL10	0.82	7.89	1.15E-19
ENSG00000134321	RSAD2	7.44	7.77	1.02E-28
ENSG00000163666	HESX1	-0.94	7.52	8.26E-18
ENSG00000184979	USP18	4.05	7.34	2.46E-27
ENSG00000187608	ISG15	8.26	7.25	8.34E-28
ENSG00000185745	IFIT1	7.54	7.06	9.44E-30
ENSG00000138646	HERC5	6.78	6.79	6.18E-30

The p values were adjusted for multiple testing by the Benjamini-Hochberg procedure.

presentation and chemoattraction, thus enhancing vaccine potency (Kang et al., 2011). It has also been demonstrated that, in the setting of DC-based tumor vaccines, modification of the vaccine through addition of IP-10 generated more tumor antigen-specific CD8⁺ T cells and stronger anti-tumor effects in vaccinated mice compared with the control group (Kang et al., 2009, 2011).

Furthermore, next-generation RNA sequencing revealed dose-dependent differential gene expression on day 1 or 3 after vaccination with CXCL10, the gene encoding for IP-10, among the 10 genes with the largest fold changes. The gene signature identified through RNA sequencing correlated with the later antibody responses and included TIFA on day 1, which is related to the IP-10 pathway. This analysis was performed in an unbiased way, not influenced by the results from markers identified through cytokine/chemokine and flow cytometry analyses.

Here we show an innate signature that correlates with the antibody response to an Ebola vaccine that not only contains transcriptional data but, indeed, a soluble factor, IP-10, in addition to surface markers found on monocytes, DCs, and NK cells, identified through flow cytometry. Our results regarding the involvement of IP-10 in the early signature were consistent when analyzing gene expression levels instead of soluble and phenotypic markers. The transcriptional profiling analysis obtained through RNA sequencing (RNA-seq) in this Ebola vaccine trial now allows for a comprehensive systems vaccinology approach studying the only Ebola candidate vaccine, rVSV-ZEBOV, anticipated for licensure this year. In-depth characterization of immune responses as presented here, with early and frequent sampling, is usually also limited to and only feasible in a relatively small number of samples and participants. External validation datasets were not available, and the small sample size inherent to a phase I trial did not allow for splitting our own data into a test and validation set. However, we did perform statistical cross-validation and bootstrapping, which is a standard approach to assess the predictive capacity of a model in the context of a small sample size.

In conclusion, a systems vaccinology approach to comprehensively analyze high-dimensional innate immune markers allowed for the identification of two unique innate immune signatures as correlates of antibody induction following vaccination

with the viral vector vaccine rVSV-ZEBOV. Our findings support efforts to further investigate the role of IP-10 to enhance vaccine immunogenicity. Together with studies confirming the immune correlates of protection from Ebola virus disease, this could ultimately lead to future studies testing IP-10 as an adjuvant for prophylactic vaccines.

EXPERIMENTAL PROCEDURES

Flow Cytometry Analysis

PBMCs from days 0, 1, 3, 7, and 14 were obtained after Ficoll-Hypaque density gradient centrifugation of whole blood. At the same time, plasma was collected from each participant for further cytokine/chemokine analysis. PBMC samples were frozen in liquid nitrogen, thawed, stained, and acquired on an LSR Fortessa flow cytometer. For analysis of monocytes and distinction of DCs, samples were stained with CD56 (HCD56, catalog number 318316), CD3 (UCHT1, catalog number 300424), C19-Alexa 700 (HIB19, catalog number 302226), CD16-allophycocyanin (APC)-Cy7 (3G8, catalog number 302018), CD14-BV711 (M5E2, catalog number 301838), CD303 peridinin-chlorophyll proteins (PerCP)/Cy5.5 (201A, catalog number 354210), CD11c-APC (3.9, catalog number 301614), human leukocyte antigen (HLA)-antigen D-related (DR)-BV785 (L243, catalog number 307642), CD83-BV421 (HB15e, catalog number 305324), CD86-phycoerythrin (PE) Dazzle (IT2.2, catalog number 305434), CD40-PE (5C3, catalog number 334308), CD1c-fluorescein isothiocyanate (FITC) (L161, catalog number 331518), CD141-PE/Cy7 (M80, catalog number 344110), and CCR7-BV605 (G043H7, catalog number 353224). For characterization of NK cells, samples were stained with two panels: panel 1, CD3 (UCHT1)/CD19 (HIB19)/CD14 (HCD14)-Alexa 700, CD56 BV605 (HCD56, catalog number 318334), CD16-APC-Cy7 (3G8), NKG2A-FITC (Miltenyi Biotec, REA110), NKG2D-PerCP/Cy5.5 (1D11, catalog number 320818), Cd161-BV421 (HP-3G10, catalog number 339914), CD57-PE Dazzle (HNC-1, catalog number 359620), CD69-PE-Cy7 (FN50, catalog number 310912), anti-KIR2DE-PE (Miltenyi, clone NKVFS1, order number 130-092-688), KIR 3DL1/DL2-PE (Miltenyi, clone 5.133, order number 130-095-205), DNAM-1-APC (11A8, catalog number 338312), and CD38-BV711 (HIT2, catalog number 303528); panel 2, CD3/CD19/CD14-Alexa 700, CD56 BV605, CD16-APC-Cy7, 2B4-APC (C1.7, catalog number 329512), NKp30-PE (P30-15, catalog number 325208), CXCR6-BV421 (K041E5, catalog number 356014), NKG2C-AF488 (R&D Systems, clone 134591, order number FAB138G-100), and NKp46-PE-Cy7 (9E2, catalog number 331916).

If not stated otherwise, antibodies were purchased from BioLegend, and clones are stated within parenthesis. Dead cells were identified and then excluded from analysis by staining samples with LIVE/DEAD Zombie Aqua Dye (BioLegend). Data were analyzed using Flow Jo v.10. For the gating strategy of NK cells, DCs, and monocytes, see Figure S14. The investigator was not blinded to dose group or time point.




Figure 6. IP-10 Gene Expression Pathway

(A) Pathway analyses of the TIFA gene, detected in the early gene expression signature, with regards to the IP-10 (CXCL-10) pathway.

(B) Observed correlations between TIFA gene expression on day 1, representative intermediate genes of the CXCL-10 pathway on day 1, CXCL10 gene expression on day or 3, and plasma IP-10 cytokine concentration on day 1 or 3; Pearson correlation coefficients are shown.

TIFA, TRAF-interacting protein with forkhead-associated domain; NFKB1, NF- κ B subunit 1; NFKB2, NF- κ B subunit 2; CHUK, conserved helix-loop-helix ubiquitous kinase; IKBKB, inhibitor of NF- κ B kinase subunit beta; IKBKE, inhibitor of NF- κ B kinase subunit epsilon; IKBKG, inhibitor of NF- κ B kinase subunit gamma; TNFRSF1A, TNF receptor superfamily member 1A; TRAF2, TNF receptor-associated factor 2; CXCL10, C-X-C motif chemokine ligand 10; IP-10, plasma IP-10 cytokine concentration; IKK complex, I κ B kinase complex; Nf κ B complex, nuclear factor κ B complex. See also [Figures S4](#) and [S5](#).

Cytokine and Chemokine Multiplex Analysis

Plasma samples from the 20 vaccinees investigated here were collected on days 0, 1, 3, 7, and 14 after vaccination and stored at -80°C prior to analysis. The assay was performed with an 11-Bioplex from Bio-Rad consisting of IFN- γ , IL-2, IL-6, IL-10, TNF- α , IL-12, MCP-1, MIP-1 β , IL-1RA, and IP-10, with addition of IFN- α and TNF- β to make it a 13-plex assay. Samples were read in duplicates according to the manufacturer's protocol on a Bio-Plex Lumines-200 (Bio-Rad) and analyzed using Bio-Plex Manager software.

RNA Extraction and Next-Generation RNA Sequencing

Whole blood from participants was directly collected into Paxgene RNA tubes (PreAnalytiX, QIAGEN) on days 0, 1, 3, and 7 after vaccination. All blood collection tubes were inverted for mixing immediately after collection and stored at room temperature before storage at -80°C , as indicated in the manufacturer's protocol. RNA isolation of thawed samples was performed according to the manufacturer's directions (PAXgene Blood RNA Kit Handbook, version 2, 2015) using the PAXgene blood RNA kit (PreAnalytiX, QIAGEN), including an optional DNase digestion step. Extracted RNA from all samples was stored at -80°C .

From total RNA, mRNA was extracted using the NEBNext Poly(A) mRNA magnetic isolation module (New England Biolabs), and RNA-seq libraries were generated using the NEBNext Ultra RNA Library Prep Kit for Illumina (NEB) according to the manufacturer's recommendations. The size and quality of the libraries were visualized on a BioAnalyzer high-sensitivity chip (Agilent Technologies), and concentrations were determined with the Qubit 2.0 fluorometer (Life Technologies). Diluted libraries were multiplex-sequenced on the Illumina HiSeq 2500 instrument (single read, 50-bp run). Samples with RNA integrity number (RIN) < 8 , with insufficient library concentration, or with a sequencing depth ≤ 5 million reads were excluded from the analyses.

Among the included samples, the median sequencing depth was 45 million reads (interquartile range, 40–52 million).

Quality control of the RNA-seq raw data were performed with the FASTQC visualization software. Reads were aligned to the human reference assembly (GRCh38.p7) using STAR (v2.4.2a). The option “`quantMode GeneCounts`” was applied to estimate the reads per gene simultaneously and generate count data. All reads mapping to an exon were attributed to a given gene, and counts were done at the gene level (because isoforms and splice variants were not a focus of this study). Multimapper was excluded from the count. Gene annotation was obtained from Ensembl (release 79, <http://www.ensembl.org>).

Statistics

The sample size of this phase I, non-randomized, open-label, dose escalation study with $n = 10$ trial participants per dose group was designed to assess major safety risks as the primary endpoint, the results of which have been published previously (Agnandji et al., 2016). The present ancillary study used all samples from all trial participants in the two reported dose groups. For assessment of the early correlates of antibody responses, we pooled both dose groups because our objective was to assess whether an early innate immune signature would be a correlate of the later antibody response regardless of the dose level received and because the sample size was too small to allow for stratified analyses. Moreover, the individual distributions of IP-10 levels and antibody levels indicate that, although a dose effect is visible, response levels overlap between groups.

All statistical tests were two-sided. Wilcoxon signed-rank test results were corrected for test multiplicity using the adaptive FDR method (Benjamini and Hochberg, 2000).

For integrative statistical analyses, sPLS (Lé Cao et al., 2008; Boulesteix and Strimmer, 2007; Liquet et al., 2012, 2016) gathers a dimension-reduction

approach together with a variable selection and a regression method. It is thus suited for the analysis of high-dimensional datasets, with highly correlated explanatory variables (such as innate immune response variables), and can leverage multivariate outcomes at once (namely EBOV-Kikwit-specific GP antibody level on day 28, and EBOV-Gueckedou-specific GP antibody levels on days 28, 56, 84, and 180) while taking into account the within-subject correlation. The final sPLS model was selected through cross-validated mean squared error of prediction (MSEP) and proportion of explained variance, whereas final multivariable linear regression models were selected using cross-validated RSR as well as a goodness-of-fit criterion (adjusted coefficient of determination, R^2). All variables were centered and reduced for sPLS analyses, whereas original variables were used in the multivariable linear model (for interpretation in their biological measurement units). Missing values were imputed (among the four cell populations finally selected by sPLS, this only concerns CXCR6 for one participant).

The analyses of differential gene expression after vaccination included all available RNA-seq data (56 samples from 18 participants) and used the voom/limma pipeline (Law et al., 2014). We tested the null hypothesis of \log_2 fold change = 0 (compared with day 0) for each gene. Multiplicity-adjusted $p < 0.05$ using FDR control (Benjamini and Hochberg, 1995) was considered statistically significant.

For the integrative analyses assessing early gene expression correlates of later antibody responses, we used the normalized gene expression levels on days 1, 3, and 7 as predictor variables, and all genes with a mean raw count > 5 (18,301 per time point) were included in these analyses. Participants with intermittently missing RNA-seq samples (i.e., at most 2 of the 3 time points missing) were included in the analyses, the missing RNA-seq data being imputed using the matrix completion package softImpute (Mazumder et al., 2010). sPLS models were then used to down-selected the predictor genes correlating with the multivariate antibody response measurements, similar to the cytokine and cell population integrative analyses. The robustness of the selection was assessed through 1,000-fold bootstrap.

Statistical analyses were performed with R software, version 3.2.2 (The R Foundation, Vienna, Austria). Pathway analyses were performed with Ingenuity Pathways Analysis software, version v31813283 (QIAGEN). Additional details regarding experimental procedures are shown in the [Supplemental Experimental Procedures](#).

Institutional Permission

All trial participants gave informed consent, and the clinical trial protocol received ethics approval (Ethik-Kommission Ärztekammer Hamburg and WHO Ethics Committee) and regulatory clearance through the competent authority (Paul Ehrlich Institute). Written informed consent was received from participants prior to inclusion in the study (ClinicalTrials.gov NCT02283099). The two groups of trial participants included 13 male and 7 female participants aged between 18 and 55 years.

ACCESSION NUMBERS

The accession number for the RNA-seq data reported in this paper is NCBI GEO: GSE97590.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, and four tables and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2017.08.023>.

AUTHOR CONTRIBUTIONS

The work presented here was carried out in collaboration between all authors. M.M.A., M.A., and R.T. made substantial contributions to conception and design and interpretation of data and participated in critically revising the manuscript for important intellectual content. A.R., L.R., and H.L. made substantial contributions to conception and design and analysis and interpretation of data. A.R. and L.R. drafted the manuscript. A.R. also participated in acqui-

sition of data. G.M., B.P.H., C.D., R.K., H.C.S., M.E.Z., V.K., S.B., and M.E. made substantial contributions to conception and design and acquisition of data and participated in critically revising the manuscript for important intellectual content. A.W.L. and the VEBCON Consortium made substantial contributions to conception and design and participated in critically revising the manuscript for important intellectual content. All authors read and gave final approval of the version to be submitted and any revised version.

CONSORTIUM

The members of VEBCON are Selidji Todagbe Agnandji, Sanjeev Krishna, Peter G. Kremsner, Jessica S. Brosnahan, Philip Bejon, Patricia Njuguna, Marylyn M. Addo, Stephan Becker, Verena Krähling, Claire-Anne Siegrist, Angela Huttner, Marie-Paule Kieny, Vasee Moorthy, Patricia Fast, Barbara Savarese, and Olivier Lapujade.

ACKNOWLEDGMENTS

We thank all volunteers for participation in the trial. We thank Henri Bonnabau (SISTM, INSERM U1219/Inria, University of Bordeaux) for help with data management. We also thank Stephanie Jost (Harvard Medical School Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center, Boston) for critically reading the manuscript and giving helpful comments. This work was funded by the German Center for Infection Research (DZIF), the Universitätsklinikum Hamburg-Eppendorf (legal sponsor), Wellcome Trust, the German Ministry for Education and Research (BMBF) through the Ebokon program and the German Ministry of Health (BMG). A.R. was supported by DZIF through a MD/Ph.D. stipend and through the Clinician Scientist Program of the Faculty of Medicine, University Medical Center Hamburg-Eppendorf (Hamburg, Germany). L.R. and R.T. are also involved in the EU-IMI-2-funded EBOVAC2 project assessing Ebola candidate vaccines from Johnson and Johnson and Bavarian Nordic and in the PREVAC project (funded by NIH and INSERM) assessing Ebola candidate vaccines from Merck, Johnson and Johnson, and Bavarian Nordic.

Received: August 18, 2016

Revised: June 21, 2017

Accepted: August 2, 2017

Published: August 29, 2017

REFERENCES

- Agnandji, S.T., Huttner, A., Zinser, M.E., Njuguna, P., Dahlke, C., Fernandes, J.F., Yerly, S., Dayer, J.A., Kraehling, V., Kasonta, R., et al. (2016). Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. *N. Engl. J. Med.* **374**, 1647–1660.
- Barouch, D.H., Liu, J., Peter, L., Abbink, P., Iampietro, M.J., Cheung, A., Alter, G., Chung, A., Dugast, A.S., Frahm, N., et al. (2013). Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). *J. Infect. Dis.* **207**, 248–256.
- Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. B* **57**, 289–300.
- Benjamini, Y., and Hochberg, Y. (2000). On the adaptive control of the false discovery rate in multiple testing with independent statistics. *J. Educ. Behav. Stat.* **25**, 60–83.
- Betancourt, D., de Queiroz, N.M., Xia, T., Ahn, J., and Barber, G.N. (2017). Cutting Edge: Innate Immune Augmenting Vesicular Stomatitis Virus Expressing Zika Virus Proteins Confers Protective Immunity. *J. Immunol.* **198**, 3023–3028.
- Boulesteix, A.L., and Strimmer, K. (2007). Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. *Brief. Bioinform.* **8**, 32–44.

- Bukreyev, A., Rollin, P.E., Tate, M.K., Yang, L., Zaki, S.R., Shieh, W.J., Murphy, B.R., Collins, P.L., and Sanchez, A. (2007). Successful topical respiratory tract immunization of primates against Ebola virus. *J. Virol.* *81*, 6379–6388.
- Christensen, J.E., de Lemos, C., Moos, T., Christensen, J.P., and Thomsen, A.R. (2006). CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. *J. Immunol.* *176*, 4235–4243.
- Dufour, J.H., Dziejman, M., Liu, M.T., Leung, J.H., Lane, T.E., and Luster, A.D. (2002). IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. *J. Immunol.* *168*, 3195–3204.
- Fanslow, W.C., Clifford, K.N., Seaman, M., Alderson, M.R., Spriggs, M.K., Armitage, R.J., and Ramsdell, F. (1994). Recombinant CD40 ligand exerts potent biologic effects on T cells. *J. Immunol.* *152*, 4262–4269.
- Feldmann, H., Jones, S.M., Daddario-DiCaprio, K.M., Geisbert, J.B., Ströher, U., Grolla, A., Bray, M., Fritz, E.A., Fernando, L., Feldmann, F., et al. (2007). Effective post-exposure treatment of Ebola infection. *PLoS Pathog.* *3*, e2.
- Furman, D., Jovic, V., Kidd, B., Shen-Orr, S., Price, J., Jarrell, J., Tse, T., Huang, H., Lund, P., Maecker, H.T., et al. (2013). Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. *Mol. Syst. Biol.* *9*, 659.
- Gaucher, D., Therrien, R., Kettaf, N., Angermann, B.R., Boucher, G., Filali-Mouhim, A., Moser, J.M., Mehta, R.S., Drake, D.R., 3rd, Castro, E., et al. (2008). Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. *J. Exp. Med.* *205*, 3119–3131.
- Geisbert, T.W., Daddario-DiCaprio, K.M., Lewis, M.G., Geisbert, J.B., Grolla, A., Leung, A., Paragas, J., Matthias, L., Smith, M.A., Jones, S.M., et al. (2008). Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. *PLoS Pathog.* *4*, e1000225.
- Geisbert, T.W., Geisbert, J.B., Leung, A., Daddario-DiCaprio, K.M., Hensley, L.E., Grolla, A., and Feldmann, H. (2009). Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. *J. Virol.* *83*, 7296–7304.
- Henao-Restrepo, A.M., Camacho, A., Longini, I.M., Watson, C.H., Edmunds, W.J., Egger, M., Carroll, M.W., Dean, N.E., Diatta, I., Doumbia, M., et al. (2017). Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). *Lancet* *389*, 505–518.
- Jones, S.M., Feldmann, H., Ströher, U., Geisbert, J.B., Fernando, L., Grolla, A., Klenk, H.D., Sullivan, N.J., Volchkov, V.E., Fritz, E.A., et al. (2005). Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. *Nat. Med.* *11*, 786–790.
- Kang, T.H., Bae, H.C., Kim, S.H., Seo, S.H., Son, S.W., Choi, E.Y., Seong, S.Y., and Kim, T.W. (2009). Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency. *J. Gene Med.* *11*, 889–898.
- Kang, T.H., Kim, K.W., Bae, H.C., Seong, S.Y., and Kim, T.W. (2011). Enhancement of DNA vaccine potency by antigen linkage to IFN- γ -inducible protein-10. *Int. J. Cancer* *128*, 702–714.
- Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014). voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol.* *15*, R29.
- Lê Cao, K.A., Rossouw, D., Robert-Granié, C., and Besse, P. (2008). A sparse PLS for variable selection when integrating omics data. *Stat. Appl. Genet. Mol. Biol.* *7*, 35.
- Li, S., Roupaphel, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., Schmidt, D.S., Johnson, S.E., Milton, A., Rajam, G., et al. (2014). Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. *Nat. Immunol.* *15*, 195–204.
- Liquet, B., Lê Cao, K.A., Hocini, H., and Thiébaud, R. (2012). A novel approach for biomarker selection and the integration of repeated measures experiments from two assays. *BMC Bioinformatics* *13*, 325.
- Liquet, B., de Micheaux, P.L., Hejblum, B.P., and Thiébaud, R. (2016). Group and sparse group partial least square approaches applied in genomics context. *Bioinformatics* *32*, 35–42.
- Lu, P., Urban, J.F., Zhou, X.D., Chen, S.J., Madden, K., Moorman, M., Nguyen, H., Morris, S.C., Finkelman, F.D., and Gause, W.C. (1996). CD40-mediated stimulation contributes to lymphocyte proliferation, antibody production, eosinophilia, and mastocytosis during an in vivo type 2 response, but is not required for T cell IL-4 production. *J. Immunol.* *156*, 3327–3333.
- Marzi, A., Robertson, S.J., Haddock, E., Feldmann, F., Hanley, P.W., Scott, D.P., Strong, J.E., Kobinger, G., Best, S.M., and Feldmann, H. (2015). EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. *Science* *349*, 739–742.
- Mazumder, R., Hastie, T., and Tibshirani, R. (2010). Spectral Regularization Algorithms for Learning Large Incomplete Matrices. *J. Mach. Learn. Res.* *11*, 2287–2322.
- Mitchell, L.A., Henderson, A.J., and Dow, S.W. (2012). Suppression of vaccine immunity by inflammatory monocytes. *J. Immunol.* *189*, 5612–5621.
- Nakaya, H.I., Wrammert, J., Lee, E.K., Racioppi, L., Marie-Kunze, S., Haining, W.N., Means, A.R., Kasturi, S.P., Khan, N., Li, G.M., et al. (2011). Systems biology of vaccination for seasonal influenza in humans. *Nat. Immunol.* *12*, 786–795.
- Paust, S., and von Andrian, U.H. (2011). Natural killer cell memory. *Nat. Immunol.* *12*, 500–508.
- Paust, S., Gill, H.S., Wang, B.Z., Flynn, M.P., Moseman, E.A., Senman, B., Szczepanik, M., Telenti, A., Askenase, P.W., Compans, R.W., and von Andrian, U.H. (2010). Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. *Nat. Immunol.* *11*, 1127–1135.
- Pulendran, B., Li, S., and Nakaya, H.I. (2010). Systems vaccinology. *Immunity* *33*, 516–529.
- Qiu, X., Fernando, L., Alimonti, J.B., Melito, P.L., Feldmann, F., Dick, D., Ströher, U., Feldmann, H., and Jones, S.M. (2009). Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. *PLoS ONE* *4*, e5547.
- Querec, T.D., Akondy, R.S., Lee, E.K., Cao, W., Nakaya, H.I., Teuwen, D., Pirani, A., Gernert, K., Deng, J., Marzolf, B., et al. (2009). Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. *Nat. Immunol.* *10*, 116–125.
- Sansom, D.M., Manzotti, C.N., and Zheng, Y. (2003). What's the difference between CD80 and CD86? *Trends Immunol.* *24*, 314–319.
- Shimaoka, T., Kume, N., Minami, M., Hayashida, K., Kataoka, H., Kita, T., and Yonehara, S. (2000). Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. *J. Biol. Chem.* *275*, 40663–40666.
- Teigler, J.E., Iampietro, M.J., and Barouch, D.H. (2012). Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. *J. Virol.* *86*, 9590–9598.
- Warfield, K.L., Perkins, J.G., Swenson, D.L., Deal, E.M., Bosio, C.M., Aman, M.J., Yokoyama, W.M., Young, H.A., and Bavari, S. (2004). Role of natural killer cells in innate protection against lethal ebola virus infection. *J. Exp. Med.* *200*, 169–179.
- Warfield, K.L., Swenson, D.L., Olinger, G.G., Kalina, W.V., Aman, M.J., and Bavari, S. (2007). Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. *J. Infect. Dis.* *196* (Suppl 2), S430–S437.
- Wong, G., Richardson, J.S., Pillet, S., Patel, A., Qiu, X., Alimonti, J., Hogan, J., Zhang, Y., Takada, A., Feldmann, H., and Kobinger, G.P. (2012). Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. *Sci. Transl. Med.* *4*, 158ra146.

Cell Reports, Volume 20

Supplemental Information

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV


Anne Rechten, Laura Richert, Hadrien Lorenzo, Gloria Martrus, Boris Hejblum, Christine Dahlke, Rahel Kasonta, Madeleine Zinser, Hans Stubbe, Urte Matschl, Ansgar Lohse, Verena Krähling, Markus Eickmann, Stephan Becker, VEBCON Consortium, Rodolphe Thiébaud, Marcus Altfeld, and Marylyn Addo

1 **Supplemental Information**

2 **Supplemental Figures and Legends**

3

4



5

6 **Figure S1. Distributions of glycoprotein-specific antibodies before (D0) and after (D28) rVSV-ZEBOV**
7 **vaccination per dose group. Related to Figure 3.**


8 Left panel: Gueckedou GP-specific-antibody levels per dose group. Right panel: Kikwit GP-specific-antibody
9 levels per dose group.

10 The 3x10⁶ pfu group is shown in blue, the 20x10⁶ pfu group is shown in orange. Negative OD values of Gueckedou
11 GP-specific-antibody levels were imputed as the lowest positive observed OD value (0.003).

12 Graphs show box plots with 1st quartile, median, 3rd quartile. The whiskers correspond to 1.5 times the
13 interquartile range.


14

15



16
 17
 18
 19
 20
 21
 22
 23
 24


Figure S2. Correlation matrix (Pearson correlation coefficients) between the five early immune response markers selected by sPLS (n=20 trial participants). Related to Figure 4.
 The matrix depicted shows positive correlations in blue and the negative correlations are shown in red. The stronger the intensity of the color, the stronger is the correlation.



25
26
27
28
29
30
31
32
33
34

Figure S3. Differentially expressed genes after vaccination at Day 1 per dose group. Related to Figure 5. Each dot corresponds to a gene, plotted according to its mean log expression on the x-axis and its log fold change on the y-axis. Red dots indicate statistically significant differentially expressed genes. Dose group 1: 3×10^6 PFU; dose group 2: 20×10^6 PFU

Analysis: VSV ZEBOV DE genes Day 1 (H0 FC=0) - 2017-06-01 10:18 PM



© 2000-2017 QIAGEN. All rights reserved.


36

37

38 **Figure S4. Top enriched canonical pathways of differentially expressed genes at Day 1.** Related to Figure 5.

39 All statistically significant differentially expressed genes at Day 1 in comparison to Day 0 (10,123 genes with
40 Benjamini-Hochberg adjusted p-value < 0.05) were included in the canonical pathway analyses (Ingenuity Pathway
41 Analysis Software).

42 The negative log P value along the left y-axis increases with increasing statistical significance of a pathway. The
43 ratio (right y-axis) indicates the proportion of modulated genes relative to all genes present in a given pathway.
44



45

46 **Figure S5. Heatmap for the 15 genes selected by sPLS at the concerned time point and the 5 antibody**
 47 **responses. Related to Figure 6.**

48 The matrix shows positive correlations between the genes and the antibody responses in blue and negative
 49 correlations in red. The stronger the intensity of the color, the stronger is the correlation. The bars on top of the
 50 figure reflect the day of the gene expressions.

51


52

53

54

55

56



57 **Figure S6. Individual changes in TIFA gene expression over timepoints day 0, 1, 3, and 7.** Related to Figure 6.
 58 Each line corresponds to an individual trial participant. The bold line corresponds to the mean.
 59

60 **Supplemental Tables and Legends**

61

62 **Table S2. Properties of the final sPLS model of early innate immune responses. Related to Figure 4.**

63

			MSEP	Q ²	Explained variance (%)*	
		Strain	Day			
Response variables	GP-specific-antibodies (stand.log.)	Kikwit	28	0.93	0.22	49
		Gueckedou	28	0.65	0.44	65
			56	0.72	0.42	64
			84	0.77	0.45	67
			180	0.94	0.31	51
Predictor variables	Plasma IP-10	3			44	
	Frequency of CD56 ^{bright} NK cells	3			40	
	MFI of CXCR6 on CD56 ^{dim} NK cells	1			51	
	Frequency of CD86+ mDCs	3			37	
	Frequency of CD86+ inflammatory monocytes	3			38	

64

65 *Explained variance of response variables (upper part) corresponds to the percentage of variance of each antibody
 66 response variable explained by the sPLS component of the five innate predictor markers. Explained variance by each
 67 predictor variable (lower part) corresponds to the variance of the response sPLS component (across the five antibody
 68 response measurements), explained by each individual predictor variable.

69 MSEP (mean squared error of prediction): the lower the MSEP, the better are the prediction properties. Q²: Q²
 70 criterion is satisfied if the value is above the threshold of 0.95

71 % of explained variance: The higher the percentage, the better the explanatory properties.

72

73

74

75 **Table S3. Pearson correlation coefficients of between the five innate markers selected by sPLS and the five**
 76 **antibody response measurements. Related to Figure 4.**

	<i>Strain</i>	GP-specific-antibodies (log)				
		<i>Kikwit</i>	<i>Gueckedou</i>			
		<i>Day</i>	28	28	56	84
IP-10 plasma concentration on day 3	<i>r</i>	0.76	0.68	0.60	0.54	0.42
	<i>p</i>	<10 ⁻⁴	<10 ⁻³	<10 ⁻²	0.01	0.07
Frequency of CD56 ^{bright} NK cells on day 3	<i>r</i>	0.52	0.57	0.56	0.60	0.59
	<i>p</i>	0.02	0.01	0.01	0.01	0.01
MFI of CXCR6 on CD56 ^{dim} NK cells on day 1	<i>r</i>	0.56	0.67	0.66	0.69	0.63
	<i>p</i>	0.01	<10 ⁻³	<10 ⁻²	<10 ⁻³	<10 ⁻²
Frequency of CD86+ mDCs on day 3	<i>r</i>	-0.38	-0.51	-0.63	-0.68	-0.53
	<i>p</i>	0.10	0.02	<10 ⁻²	<10 ⁻³	0.02
Frequency of CD86+ inflammatory monocytes on day 3	<i>r</i>	-0.31	-0.58	-0.64	-0.66	-0.56
	<i>p</i>	0.18	0.01	<10 ⁻²	<10 ⁻²	0.01

77 Pearson correlation coefficients and raw p-values are reported

78

79

80

81

82

83

84

85

86

87


88

89

90

91

92 **Supplemental Experimental Procedures**



93


94 **Workflow to assess vaccine-induced innate immune signatures.**

95 Samples were available from participants in the open-label, dose-escalation single-center phase 1 trial
 96 conducted at the UKE in Hamburg and included 20 healthy male and female participants between 18 and
 97 55 years of age, which were enrolled into two dose groups, consisting of 10 vaccinees each. Group 1
 98 received 3×10^6 pfu of the rVSV-ZEBOV vaccine, and group 2 received the highest dose of 20×10^6 pfu as
 99 a single injection on day 0. Blood samples from the vaccinees were obtained on day 0 (pre-vaccination),
 100 as well as days 1, 3, 7 and 14 after vaccination to analyze early vaccine-induced innate immune
 101 responses. Study participants were enrolled between November and December 2014 and followed up for
 102 6 months. The study at the UKE was one of four harmonized investigator-initiated phase 1 trials
 103 coordinated through the VEBCON to assess the safety and immunogenicity of ascending doses of rVSV-
 104 ZEBOV in Gabon, Kenya, Germany and Switzerland, and to facilitate rapid progression to phase 2 and 3
 105 trials in affected countries.


106

107

108
 109
 110 A
 111
 112



113 B




114
 115 **Model selection criteria of the sPLS model of innate cell populations and cytokines.**

116 (A) Properties of the first sPLS component as a function of the number of selected predictor variables. The Mean
 117 Squared Error in Prediction (MSEP) is minimal (i.e. best) for the majority of the response variables when five
 118 predictor variables are selected on the first sPLS component. The percentage of variance of each response variable
 119 explained by a given number of predictor variables in the first sPLS component reaches its maximum between 12
 120 and 20 predictor variables for four of the response variables, but the additional gain in percentage of variance
 121 explained per additional predictor variable slows down (change in slope) around 5 predictor variables. The Q^2
 122 criterion for five predictor variables lies above the threshold of 0.095, indicating that the first sPLS component with
 123 these predictor variables carries relevant information for the model.


124 (B) Q^2 criterion for a second component of predictor variables in the sPLS model. With five selected predictor
 125 variables, given the indicators for the first sPLS component (see panel A), a second sPLS component would not
 126 carry relevant information for the model (Q^2 criterion below the threshold of 0.095 and is thus not further considered
 127 in the model). Overall, the sPLS model describes and predicts the Gueckedou GP-specific antibody responses (d28,

128 56, 84) more accurately, most likely as multiple measurements are available for this antibody type, compared to
 129 Kikwit GP-specific antibody responses (only d28).
 130 **Predicted versus observed values for each antibody responses variables between d28 and d180 based on the**
 131 **five early cell population and cytokine immune response markers selected by sPLS (n=20 trial participants).**
 132








133 **Distribution of the residuals of the final multivariable linear model predicting the day 28 Gueckedou GP-**
 134 **specific antibody response.**
 135 Final multivariable linear model predicting Gueckedou GP-specific antibody response on day 28 (in log optical
 136 density) with IP-10 plasma concentration on day 3 and MFI of CXCR6 on CD56^{dim} NK cells on day 1 as predictors.
 137 The residual for each of the 20 participants shows the part of information in his/her Gueckedou GP-specific antibody
 138 response on day 28 that is not explained by the model.
 139

140
 141
 142
 143




144 **Model selection criteria of the sPLS model of gene expression.**
 145 Properties of the first sPLS component as a function of the number of selected predictor variables. The Mean
 146 Squared Error in Prediction (MSEP) is minimal (i.e. best) for the majority of the response variables when 15
 147 predictor variables are selected on the first sPLS component.
 148
 149
 150



151

152 Predicted versus observed values for each antibody responses variables between d28 and d180 based on the
 153 15 gene expression variables selected by sPLS.

154



155

156

157 **Bootstrapping results of the genes selected by the sPLS model**

158 1000-fold bootstrapping. Proportions of bootstrapping samples selecting the given gene are shown for the top 20
159 genes identified.

160

161

162


163

164

165

166


A



167


168

B



169

C



170

171 **Gating strategy for flow cytometry of NK cells, DCs and monocytes.** Cryopreserved PBMC samples were
 172 thawed and analyzed through flow cytometry as indicated in *Material and Methods*. (A) First step in gating strategy
 173 for DCs and NK cells for selection of lymphocytes, singlets and exclusion of dead cells. (B) Gating strategy for NK
 174 cells (C) Gating strategy for DCs and monocytes.

175 **Supplemental Statistical Information**

176 Partial Least Squares (PLS) regression gathers a dimension-reduction approach together with a regression method. It
177 is suited for the analysis of datasets with a large number of variables and a relatively small sample size and searches
178 the optimal linear combinations of multidimensional, highly correlated, explanatory variables (here innate immune
179 response variables), which best explain the variability in the multivariate outcome (here antibody responses). The
180 linear combinations of variables are summarized in latent components. The sparse version, sPLS, allows for variable
181 down-selection by including a Lasso penalization (Le Cao et al., 2008, Boulesteix and Strimmer, 2007, Liquet et al.,
182 2012, Liquet et al., 2016). The number of PLS components and the number of variables per component were
183 optimized using the PLS Q criterion and the cross-validation prediction error (mean squared error of prediction
184 (MSEP), leave-one-out), respectively. This method allowed for down-selection of early innate markers explaining
185 most of the variability in the antibody responses (Liquet et al., 2012, Liquet et al., 2016).

186 The predictive value of the multivariable linear model was assessed by the root square residuals (RSR), which is the
187 ratio of the root mean square error between predicted and observed values to the standard deviation of the
188 observations.

189 Missing values of cell surface markers were imputed by non-parametric simple imputation based on Random
190 Forests, a method that takes into account the multidimensional and correlated nature of the immune markers
191 (Breiman, 2001). Values of cytokine concentrations below the standard curve were also imputed, based on Gaussian
192 Kernel estimation of the density function windowed between 0 and the corresponding Low Level Of Quantification
193 (LLOQ) of the standard curve. The cytokine marker selected by sPLS (IP-10 plasma concentration on day 3) was
194 not concerned by this imputation.

195 For the analyses of differential gene expression after vaccination, we used the voom/limma pipeline, an empirical
196 Bayes estimation of a linear model accounting for the inherent heteroscedasticity of RNA-seq data pipeline for
197 differential expression analyses of RNA Seq data (Law et al., 2014). We first applied a filter to exclude genes with
198 very low mean count from statistical comparisons (exclusion of genes with mean raw count <5) and then used TMM
199 (Trimmed Mean of M-values) normalization and logCPM (logarithm of counts per million reads) transformation.
200 TMM allows for between-sample normalization under the null hypothesis and serves as correction factor for library
201 size in the analyses (Robinson and Oshlack, 2010). The voom method relies on linear modelling of logCPM
202 transformed normalized data, with TMM library size correction, with an estimation of mean-variance trend through
203 a LOWESS curve. This non-parametric approach avoids the negative binomial distribution assumption by instead
204 estimating precision weights. Using these weights, the limma empirical Bayes analysis pipeline, based on the normal
205 linear model, can then be applied to RNA Seq data. We tested the null hypothesis of log₂ fold change =0 (compared
206 to Day 0) for each gene, and used the Benjamini-Hochberg procedure for controlling FDR to account for multiple
207 testing (Benjamini Y, 1995). Multiplicity-adjusted p-values < 0.05 were considered statistically significant.

208 In our analysis, we first applied a filter to exclude genes with very low mean count from statistical comparisons
209 (exclusion of genes with mean raw count <5) and then used TMM (Trimmed Mean of M-values) normalization and
210 logCPM (logarithm of counts per million reads) transformation. TMM allows for between-sample normalization
211 under the null hypothesis and serves as correction factor for library size in the analyses (Robinson and Oshlack,
212 2010). The voom method relies on linear modelling of logCPM transformed normalized data, with TMM library size
213 correction, with an estimation of mean-variance trend through a LOWESS curve. This non-parametric approach
214 avoids the negative binomial distribution assumption by instead estimating precision weights. Using these weights,
215 the limma empirical Bayes analysis pipeline, based on the normal linear model, can then be applied to RNA Seq
216 data. We tested the null hypothesis of log₂ fold change =0 (compared to Day 0) for each gene, and used the
217 Benjamini-Hochberg procedure for controlling FDR to account for multiple testing (Benjamini Y, 1995).

218 **Supplemental Acknowledgements**

220 **VEBCON consortium:**

221 Selidji Todagbe Agnandji (Centre de Recherches Medicales de Lambaréné, Gabon, Institut für Tropenmedizin,
222 Universitätsklinikum Tübingen, Germany) and Sanjeev Krishna (St George's University of London, UK, Institut für
223 Tropenmedizin, Universitätsklinikum Tübingen, Germany, Centre de Recherches Medicales de Lambaréné
224 Lambarene, Gabon); Peter G. Kremsner and Jessica S. Brosnahan (Institut für Tropenmedizin, Universitätsklinikum
225 Tübingen, Germany, Centre de Recherches Medicales de Lambaréné, Gabon); Philip Bejon and Patricia Njuguna
226 (Kenya Medical Research Institute, Kilifi, Kenya); Marylyn M. Addo (University Medical Center Hamburg,
227 Germany); Stephan Becker and Verena Krähling (Institute of Virology, Marburg, Germany); Claire-Anne Siegrist
228 and Angela Huttner (Geneva University Hospitals); Marie-Paule Kiény, Vasee Moorthy, Patricia Fast, Barbara
229 Savarese, Olivier Lapujade (World Health Organization, Geneva, Switzerland).

231 **Supplemental References**

232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248

BENJAMINI Y, H. Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J Roy Stat Soc Ser B* 57, pp. 289-300.

BOULESTEIX, A. L. & STRIMMER, K. 2007. Partial least squares: a versatile tool for the analysis of high-dimensional genomic data. *Brief Bioinform*, 8, 32-44.

BREIMAN, L. 2001. Random forests. *Machine Learning*, 45, 5-32.

LAW, C. W., CHEN, Y., SHI, W. & SMYTH, G. K. 2014. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol*, 15, R29.

LE CAO, K. A., ROSSOUW, D., ROBERT-GRANIE, C. & BESSE, P. 2008. A sparse PLS for variable selection when integrating omics data. *Stat Appl Genet Mol Biol*, 7, Article 35.

LIQUET, B., DE MICHEAUX, P. L., HEJBLUM, B. P. & THIEBAUT, R. 2016. Group and sparse group partial least square approaches applied in genomics context. *Bioinformatics*, 32, 35-42.

LIQUET, B., LE CAO, K. A., HOCINI, H. & THIEBAUT, R. 2012. A novel approach for biomarker selection and the integration of repeated measures experiments from two assays. *BMC Bioinformatics*, 13, 325.

ROBINSON, M. D. & OSHLACK, A. 2010. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol*, 11, R25.